Plesner advises Lundbeck on EMTN bond programme and debut issue
08 October 2020
The global pharmaceutical company H. Lundbeck A/S has just established an EMTN bond programme and a debut issue under the programme.
Plesner advised H. Lundbeck A/S on the establishment of the EMTN bond programme with BPN Paribas, Bank of America, Danske Bank, Jyske Bank, Nordea and SEB as dealers. The programme has an aggregate limit of EUR 2bn.
Plesner also advised H. Lundbeck A/S on its debut issue under the bond programme: A EUR 500m seven-year bond which on 7 October 2020 was priced at 0.875% with BNP Paribas, Danske Bank, Jyske Bank, Merrill Lynch, Nordea and SEB as joint lead managers.
The transaction confirms Plesner’s position as a leading Nordic law firm in debt capital markets transactions.
Lundbeck is a global pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at the disease areas within psychiatry and neurology. Lundbeck employs approximately 5,500 people in more than 50 countries and generated a revenue of DKK 17bn in 2019.
Plesner also advised H. Lundbeck A/S on its debut issue under the bond programme: A EUR 500m seven-year bond which on 7 October 2020 was priced at 0.875% with BNP Paribas, Danske Bank, Jyske Bank, Merrill Lynch, Nordea and SEB as joint lead managers.
The transaction confirms Plesner’s position as a leading Nordic law firm in debt capital markets transactions.
Lundbeck is a global pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at the disease areas within psychiatry and neurology. Lundbeck employs approximately 5,500 people in more than 50 countries and generated a revenue of DKK 17bn in 2019.
